Despite soaring global demand for healthcare, the challenge of profitably developing treatments has never been greater or more ethically complex. Can pharma giants strike the right balance?
Recent insights
1 septiembre 2024
The Unified patent court and unitary patent – An introduction
1 septiembre 2024
How to get a Unitary Patent
1 septiembre 2024
Which states are in the UPC & where will a UP have effect?
16 agosto 2024
Principles for setting climate targets: A guide for Australian boards
22 julio 2024
Australian Competition & Consumer Commission releases draft sustainability collaboration guidance
28 junio 2024
Helping Life Sciences companies land and expand globally
6 junio 2024
The Australian Government’s “Closing Loopholes” industrial relations reforms: What they mean for your business
20 marzo 2024
Pharma – Strong year ahead
13 marzo 2024
Generative AI: A bilateral online safety focus for Australia and the UK
30 agosto 2023
Ghostbusters: In a New Win for Providers, No Surprises Act Rules Struck for Allowing Ghost Rates
Last week, the federal government met its fourth loss in a challenge brought by health care and air ambulance providers against No Surprises Act (NSA) …
8 agosto 2023
No Surprises Here: Providers Score Third Victory in No Surprises Act Litigation, Other Challenges to the NSA Continue
Congress enacted the No Surprises Act (NSA) in 2020 to reduce surprise medical bills and to provide a simple and fast procedure for out-of-network health …
3 agosto 2023
Recent DOJ Settlement With NextGen Highlights Continued Enforcement Focus on Electronic Health Records Technology Vendors
On July 13, NextGen Healthcare Inc. (NextGen), an electronic health record (EHR) software vendor, reached an agreement with the Department of Justice …
Key contacts
Alan Montgomery
Partner, Head of Pharmaceuticals Sector, Chair of India Group, London
Chris Parker KC
Partner, Head of Pharmaceuticals Sector, London
Natalie Bryce
Partner, Brisbane